Over the past 10 years, Creative Biolabs has grown into a recognized world leader in bispecific antibody (BsAb) discovery, engineering, production, and analysis. Our products and services have been used extensively by scientists all over the world to accelerate their life science research. Here, we present a collection of representative citations.
For your convenience, we have grouped these patents & articles into the following categories:
As a leading company in the antibody development market, experts in Creative Biolabs possess enriched experience in bispecific antibody (BsAb) development. We are proud of our one-stop, customized BsAb development services, involving the design, engineering, manufacturing, and analysis of BsAbs.
The authors found that a bispecific antibody that simultaneously targets α5β1and αv integrins (BsAbα5β1/αv) was superior to monoclonal antibodies in abrogating adhesion, migration, clonogenic survival, and induction of endothelial migration responses by prostate cancer cells. Creative Biolabs helped constructing the bispecific antibody.
The authors designed single-component molecules that incorporate two (bispecific) or three (trispecific) broadly neutralizing antibody (bNAb) binding sites that recognize the human immunodeficiency virus (HIV) envelope glycoprotein (Env) or the coreceptor CCR5 or that cross-target both Env and CCR5. The initial eight trispecific design variations of 10E8Fab-PGT121fv-PGDM1400fv were generated by Creative Biolabs.
Creative Biolabs collects hot therapeutic targets and provides a variety of customized bispecific antibody (BsAb) products. Based on the advanced strategies and to fit the desired the target-product profile, we can help develop different formats of BsAbs adapted the valency, structure, half-life and biodistribution, etc.
This paper reported an automated flow cytometry assay for bispecific antibodies screening that keep intact both basal effector to target (E:T) ratios and Native environment using whole blood or bone marrow samples. The recombinant anti-CD123 x anti-CD3 bispecific antibody was obtained from Creative Biolabs.